Tag Archives: blood-brain barrier

GLP-1 Drugs Surprising Neuroprotective Qualities

Diagram of GLP-1 (7-36) amide peptide showing amino acid sequence, side chains, chemical formulas, and α-helix structure

The weight-loss drug semaglutide, sold under the names Ozempic and Wegovy, may do far more than shrink waistlines. Research suggests it could also shield the brain after traumatic injury.

A 2026 study published in Neural Regeneration Research by scientists at Beijing Tiantan Hospital, and available in the PubMed database, found that semaglutide reduced brain swelling, preserved the blood-brain barrier, and blocked dangerous inflammatory cascades in mice with traumatic brain injuries. “Our findings reveal the dual anti-inflammatory and neuroprotective roles of semaglutide, providing important preclinical evidence for its clinical application in the acute phase of traumatic brain injury,” the researchers wrote.

The possibilities are enormous. Last year, a University of Wisconsin–Madison retrospective study of more than two million stroke patients found that those taking semaglutide had a mortality rate of just 5.26%, compared with 21.61% for non-users.

While human clinical trials for TBI are still needed, scientists say GLP-1 drugs represent the most promising new avenue for brain injury treatment in decades.

Developing the “Dancing Molecule”

Northwestern University scientists have developed an injectable nanomaterial, dubbed “dancing molecules”, that cross the blood-brain barrier and shield brain tissue from post-stroke damage. Published January 2026 in Neurotherapeutics, the therapy uses tiny, constantly moving molecular assemblies, known as supramolecular therapeutic peptides (STPs), delivered intravenously that self-organize into nanofibers inside injured brain tissue. In mice, a single IV dose given after blood flow was restored significantly reduced inflammation, tissue death, and harmful immune response with no observed toxicity.

In July 2025, Amphix Bio, the company behind the treatment, posted on LinkedIn: “We are thrilled to announce the FDA has granted an Orphan Drug Designation to AMFX-200, our lead candidate based on the Supramolecular Therapeutic Peptide (STP) platform, for the treatment of acute spinal cord injury. This will accelerate our efforts to bring this novel neuro-regenerative therapeutic to the clinic.”*

* I cannot find any record of human trials of this stroke treatment, as of yet. Additionally, key limitations remain, as results are preclinical only, dosing must be precise to prevent blood clotting, and long-term human safety is unproven.